WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China

WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China

October 26, 2007

    SHANGHAI, China, Oct. 26 /Xinhua-PRNewswire/ -- WuXi
PharmaTech (NYSE: WX), China's premier provider of
pharmaceutical R&D outsourcing services announced today
that it has been ranked the 28th in the Deloitte Technology
Fast 50 China program, a ranking of the 50 fastest growing
technology companies in China.  The awards ceremony was
held in the JW Marriott Hotel Shanghai at Tomorrow Square,
Shanghai on October 25.

    (Logo: http://www.xprn.com/xprn/sa/200708281726.jpg )

    The Deloitte Technology Fast 50 China program ranks
leading companies in Technology, Media and Telecom (TMT)
sectors based on their average revenue growth rates over
the last three years.  Given China's rapid economic growth,
the strong development of the TMT industry, the government
advocating technology innovation and the appetite of local
and overseas venture capital for fast growing technology
companies, this year's revenue growth requirement for
winning has substantially increased.  As a result, more
than half of the winners are the first time winners and
only one of the top 10 winners is a previous winner.

    Ranked the 22nd, 27th and 28th in 2005, 2006 and 2007,
respectively, WuXi PharmaTech is one of the nine companies
to win the award for three consecutive years.

    "We are pleased to be recognized by Deloitte for
our accomplishments for the third time," commented Dr.
Ge Li, Chairman and Chief Executive Officer of WuXi
PharmaTech.  "As the whole industry sector enjoys
remarkable growth, WuXi PharmaTech has grown from a small
start-up to a New York Stock Exchange listed company.  I am
very proud that we still can maintain our relative rank on
the list, and I would like to take this opportunity to
thank our customers for their strong supports and employees
for their dedication and hard work," continued Dr. Li.

    About WuXi PharmaTech

    Founded in 2000, Shanghai-based WuXi PharmaTech is the
leading China-based pharmaceutical and biotechnology
R&D outsourcing company.  As a research- driven and
customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies a broad and
integrated portfolio of laboratory and research
manufacturing services throughout the drug discovery and
development process.  WuXi PharmaTech's services are
designed to assist its global partners in shortening the
cycle and lowering the cost of drug discovery and
development by providing cost-effective and efficient
outsourcing solutions that save its customers both time and
money.  Its operations are grouped into two segments:
laboratory services, consisting of discovery chemistry,
service biology, analytical, toxicology, pharmaceutical
development and process development services, and
manufacturing, focusing on manufacturing of advanced
intermediates and active pharmaceutical ingredients for
R&D use.  In 2006, WuXi PharmaTech provided services to
70 pharmaceutical and biotechnology customers, including
nine of the top ten pharmaceutical companies in the world,
as measured by 2006 total revenues.  For more information,
please visit: http://www.wuxipharmatech.com .



    For more information, please contact:
   
     Sherry Shao
     Tel:   [phone]
     Email: [e-mail]